Private equity giant KKR is in “advanced” discussions to acquire a stake in New Delhi-based SRL Diagnostics, sources told Bloomberg. The deal could value SRL at about 50 billion rupees ($775 million).
SRL, which bills itself as the largest diagnostics company in India, is being spun off from Fortis Healthcare, one of India’s largest private hospital chains, Bloomberg reported last month. Fortis has been in talks with other private equity players, including TPG and Bain Capital, Bloomberg said.
While discussions between SRL and KKR are ongoing, it’s not a done deal, said people familiar with the matter, as quoted by Bloomberg.
SRL operates 356 laboratories, including large labs in Dubai, Sri Lanka and Nepal. It has more than 5,000 collection points, with 69 of them in countries outside India, according to the company.
It offers prognostic, diagnostic and monitoring services to other pathology labs, hospitals and patients, and also serves pharma companies and CROs carrying out clinical trials.
In January last year, KKR and Panasonic—of which KKR holds an 80% stake—closed their $1.1 billion acquisition Bayer’s diabetes unit and rebranded the company as Ascensia Diabetes. As for diagnostics, KKR invested $35 million in Signostics, which specializes in miniaturized, hand-held ultrasound devices for use at the point of care.
By Amirah Al Idrus
Source: Fierce Biotech
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
